Regeneron Pharmaceuticals Inc (REGN)

Cash ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash and cash equivalents US$ in thousands 2,730,000 2,152,300 1,937,200 3,916,300 3,105,900 3,491,300 3,395,100 3,345,700 2,885,600 3,432,400 2,072,200 1,437,900 2,193,700 1,573,000 1,992,200 2,208,200 1,617,800 1,384,800 1,045,500 1,708,500
Short-term investments US$ in thousands 8,114,800 7,761,300 6,990,500 5,043,400 4,636,400 3,530,400 4,171,300 3,704,900 2,809,100 2,355,200 1,838,600 2,065,900 1,393,300 1,452,900 1,152,000 1,795,200 1,596,500 1,493,100 1,624,200 1,523,900
Total current liabilities US$ in thousands 3,423,400 3,598,600 3,104,400 3,100,100 3,141,300 2,879,200 3,033,900 3,007,600 3,932,500 3,714,800 3,732,400 3,217,800 2,697,400 2,337,800 3,702,400 2,055,200 2,096,600 1,765,400 1,713,100 1,511,400
Cash ratio 3.17 2.75 2.88 2.89 2.46 2.44 2.49 2.34 1.45 1.56 1.05 1.09 1.33 1.29 0.85 1.95 1.53 1.63 1.56 2.14

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($2,730,000K + $8,114,800K) ÷ $3,423,400K
= 3.17

The cash ratio for Regeneron Pharmaceuticals, Inc. has demonstrated a positive trend over the past eight quarters, indicating the company's strong ability to cover its short-term liabilities with cash and cash equivalents. The ratio has consistently been above 2, reflecting a healthy liquidity position for the company.

The highest cash ratio was observed in Q4 2023 at 3.28, suggesting a significant increase in the company's ability to settle its short-term obligations using its available cash resources. This indicates that the company has a substantial amount of cash on hand relative to its current liabilities.

Overall, the trend in the cash ratio for Regeneron Pharmaceuticals, Inc. indicates a strong financial position with healthy liquidity levels. It suggests that the company has the ability to meet its short-term financial obligations without the need for additional borrowing or liquidation of long-term assets.


Peer comparison

Dec 31, 2023


See also:

Regeneron Pharmaceuticals Inc Cash Ratio (Quarterly Data)